Kezar Life Sciences, Inc. (KZR)

Market Cap	34.12M
Revenue (ttm)	n/a
Net Income (ttm)	-78.63M
Shares Out	7.31M
EPS (ttm)	-10.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82
Open	n/a
Previous Close	4.790
Day's Range	n/a
52-Week Range	3.620 - 9.180
Beta	0.60
Analysts	Hold
Price Target	9.00 (+92.72%)
Earnings Date	Aug 12, 2025

About KZR

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibito...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 21, 2018
• Employees: 55
• Stock Exchange: NASDAQ
• Ticker Symbol: KZR
• Website: https://www.kezarlifesciences.com

Analyst Summary

According to 2 analysts, the average rating for KZR stock is "Hold." The 12-month stock price target is $9.0, which is an increase of 92.72% from the latest price.

Price Target

$9.0

(92.72% upside)

Analyst Consensus: Hold